Enzymotec (ENZY) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results
February 22, 2017 7:30 AM ESTMIGDAL HA'EMEQ, Israel, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the fourth quarter and full year ended December 31, 2016.
Fourth Quarter 2016 Financial and Operational Highlights
Net revenues decreased 20.2% and 7.3% to $10.6 million, compared to the fourth quarter of 2015 and the third quarter of 2016, respectively.Net revenues (utilizing the proportionate consolidation method that is used for segment reporting) decreased 19.1% and 10.9% to $13.5 million, compared to the fourth... More